ClearPoint Neuro Inc vs Snowflake Inc — how do they compare? ClearPoint Neuro Inc trades at $15.22 (market cap $454.21M), while Snowflake Inc trades at $331.5 (market cap $116.01B). The key difference: Snowflake Inc is far larger — about 255.4× ClearPoint Neuro Inc's market cap, and Snowflake Inc is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | SNOW | |
|---|---|---|
Market Cap | $454.21M | $116.01B |
Sector | Health | Technology |
52-Week High | $29.60 | $334.70 |
52-Week Low | $8.66 | $121.11 |
Enterprise Value | $488.79M | $115.82B |
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $15.18, up 4.19% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth but missed earnings expectations with a $0.38 loss per share. Despite negative profitability metrics, analyst consensus remains unanimously bullish with 100% buy ratings. Recent news highlights regulatory progress with partners and expansion of the drug delivery ecosystem.
The stock presents a high-risk opportunity with strong analyst support despite current losses. Investment thesis hinges on successful commercialization of neuro drug delivery technologies and partnership execution. Key risks include persistent negative cash flow from operations and delayed revenue ramp-up from new facilities. Upside depends on translating regulatory momentum into sustainable revenue growth.
Snowflake (SNOW) trades at $334.30, down 0.12% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong revenue growth to $3.63 billion in 2025, though net losses persist at -$1.29 billion. Recent news highlights AI platform enhancements and investor conferences, with earnings beats in the last three quarters.
Outlook remains growth-focused with AI adoption driving upside, but premium valuation (P/S 22.66) and sustained losses pose risks. Analyst consensus is bullish with an 80.77% buy rating, though competition and margin pressure require monitoring for stock investors.
Trailing returns across standard periods
Latest headlines on both assets
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →